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Early immune modulation by single-agent trastuzumab as a
marker of trastuzumab beneﬁt
Tiziana Triulzi1, Viola Regondi1, Loris De Cecco2, Maria Rosa Cappelletti3, Martina Di Modica1, Biagio Paolini4, Pier Luigi Lollini5,
Serena Di Cosimo6, Lucia Sfondrini7, Daniele Generali3,8 and Elda Tagliabue1
BACKGROUND: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC)
patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of
trastuzumab according to the response to trastuzumab.
METHODS: Gene expression proﬁles of pre- and post-treatment tumour samples from 17 HER2-positive BC patients were analysed
on the Illumina platform. Tumour-associated immune pathways and blood counts were analysed with regard to the response to
trastuzumab. HER2-positive murine models with differential responses to trastuzumab were used to reproduce and better
characterise these data.
RESULTS: Patients who responded to single-agent trastuzumab had basal tumour biopsies that were enriched in immune
pathways, particularly the MHC-II metagene. One cycle of trastuzumab modulated the expression levels of MHC-II genes, which
increased in patients who had a complete response on treatment with trastuzumab and chemotherapy. Trastuzumab increased the
MHC-II-positive cell population, primarily macrophages, only in the tumour microenvironment of responsive mice. In patients who
beneﬁted from complete trastuzumab therapy and in mice that harboured responsive tumours circulating neutrophil levels
declined, but this cell subset rose in nonresponsive tumours.
CONCLUSIONS: Short treatment with trastuzumab induces local and systemic immunomodulation that is associated with clinical
outcomes.
British Journal of Cancer (2018) 119:1487–1494; https://doi.org/10.1038/s41416-018-0318-0
BACKGROUND
The HER2 receptor is overexpressed in approximately 20% of
breast cancers (BCs) and has historically been associated with
aggressive disease and a poor prognosis. Treatment with
trastuzumab and chemotherapy has dramatically changed the
prognosis of early and advanced HER2-positive (HER2+) BC
patients.1 More recently, the introduction and availability of other
HER2-targeting agents offer clinicians the ability to provide
prolonged inhibition of HER2 signalling across multiple lines of
treatment, and the dual HER2 blockade approach has demon-
strated superior activity over trastuzumab alone. As more
potential therapies appear over the horizon, advancements in
biomarker discovery will be critical in optimising treatment
selection and providing personalised therapy for patients.
Particularly, it remains unknown which patients beneﬁt from
single-agent trastuzumab and those who require instead the dual
blockade upfront. Many efforts have been made toward identify-
ing biomarkers that predict a beneﬁt from trastuzumab: HER2
addiction and immune features have demonstrated the best
predictive ability in several trials (reviewed in ref. 2), but HER2
expression in the primary tumour remains the only marker that is
used in clinical practice.
Preclinical studies have reported that trastuzumab has
cytostatic (e.g., inhibition of HER2 signalling, extracellular
domain shedding, and tumour angiogenesis) and cytotoxic
activities [antibody-dependent cell-mediated cytotoxicity
(ADCC), antibody-dependent cell-mediated phagocytosis (ADCP),
and inhibition of DNA repair].3 In the neoadjuvant setting, the
decrease in tumour burden, or pathological complete response
(pCR), is likely to depend on the cytotoxic activity of trastuzu-
mab.4 Accordingly, increasing evidence has shown that the
therapeutic activity of trastuzumab relies on the innate and
adaptive immune systems, and the signiﬁcant pre-existing
inﬁltration of BCs by immune cells has been associated with
pCR in several trials (reviewed in ref. 5). Trastuzumab also
positively regulates inﬁltration by lymphoid cells in tumour
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tissues,6–8 supporting that its clinical activity is based on its
immunostimulatory effects.9
In this study, we analysed the gene expression proﬁle of tumour
biopsies from the TRastuzumab UPfront in HER2+ locally
advanced BC (TRUP) window-of-opportunity trial10 before and
after brief exposure to trastuzumab. We performed an exploratory
analysis of the molecular features that were associated with the
clinical activity of short-term trastuzumab monotherapy, monitor-
ing changes in immune expression on treatment as markers of
trastuzumab activity.
MATERIALS AND METHODS
Patients
The 17 tumours that we proﬁled were obtained from BC patients
in the TRUP window-of-opportunity trial,10 which comprised 28
locally advanced primary BCs that were diagnosed by incisional
biopsy at A.O. Istituti Ospitalieri di Cremona. In the TRUP study,
patients received 1 cycle of trastuzumab alone, followed by 4
cycles of trastuzumab and paclitaxel, until deﬁnitive surgery. As
per the protocol, after single-agent trastuzumab (21 days),
assessment of tumour response and research tumour biopsy
(Tru-cut biopsy) were performed. Responses at the Tru-cut biopsy
were available for all but one patient. Blood test results (i.e., blood
cell count/μl) at baseline and at the Tru-cut biopsy were retrieved
and analysed. All procedures were performed in accordance with
the Helsinki Declaration. The biospecimens that were examined
consisted of leftover material from samples that had been
collected during standard surgical and medical procedures at A.
O. Istituti Ospitalieri di Cremona. Samples were donated by
patients to the Institutional BioBank for research purposes, and
aliquots were designated for this study after approval by the
institutional review board and a speciﬁc request to the
independent ethical committee ‘Comitato Etico Val Padana’.
The response to trastuzumab after 21 days was calculated as %
reduction in clinical dimensions or in the number of Ki67-positive
cells at day 21 compared with baseline. Patients who experienced
a decrease of at least 20% in tumour volume or at least 50% in the
number of Ki67-positive cells were scored as responders. The
response rate (RR) to trastuzumab and chemotherapy was
calculated as the ratio of the difference between the initial clinical
dimensions and ﬁnal pathological dimensions to the initial clinical
dimensions, and responders were selected, based on the cut-off
RR in the original study (RR= 70%).10
Gene expression analysis
RNA was extracted from frozen incisional biopsies of the TRUP
cohort using the miRNeasy MINI KIT (Qiagen) according to the
manufacturer’s protocol. RNA quality was checked in a preanaly-
tical screen by RT-qPCR, as described.11 Gene expression proﬁles
were generated by whole-genome DASL (cDNA-mediated anneal-
ing, selection, extension, and ligation) assay using HumanHT12_v4
BeadChips (Illumina), according to a standard protocol. The
Illumina BeadArray Reader was used to scan the arrays. Illumina
BeadScan was used to acquire the images and recover the primary
data. The data were quantile-normalised using BeadStudio. The
BeadChips covered over 29,000 annotated genes that were
derived from RefSeq (Build 36.2, Release 38), and after a ﬁlter
step, a data matrix that contained 17 matched samples was
generated. The data were deposited into the Gene Expression
Omnibus repository (accession number GSE114082).
Bioinformatics analysis
Gene set enrichment analysis was performed for Reactome
pathways using GSEA v2.0.13.12 Genes that were represented by
more than 1 probe were collapsed to the probe with the
maximum value using the Collapse Dataset tool. Gene set
permutation type was applied 1000 times, and gene set
enrichment was considered to be signiﬁcant at a false discovery
rate (FDR) of <10%.
Immune metagenes were determined per Rody et al.13 The 569
Affymetrix probe sets were ﬁrst mapped using the Illumina
platform, and of the 7 immune metagenes, the IgG metagene was
excluded due to low gene number. The average log-transformed
expression of the genes that belonged to each metagene was
calculated. Cluster analysis of Rody’s metagenes was performed
using Cluster 3.0 by K-mean clustering (n= 3) and visualised using
TreeView. To estimate the abundance of immune cell types in
TRUP tumours, we applied the CIBERSORT tool to our dataset
using the LM22 signature.14
Immunoﬂuorescence and immunohistochemistry
IHC was performed on formalin-ﬁxed parafﬁn-embedded (FFPE)
tissue. Slides were deparafﬁnised in xylol and serially rehydrated,
and after antigen retrieval at 96 °C for 6 min using 10mM citrate
buffer, pH 6.0, the samples were stained with mouse monoclonal
anti-human HLA-DR/DP/DQ/DX (clone CR3/43, 1:500, Santa
Cruz Biotechnology). Immunoreactions were visualised using
streptavidin-biotin-peroxidase (Thermo Fisher Scientiﬁc) and the
DAB Chromogen System (Dako Agilent Technologies) and
counterstained with Carazzi haematoxylin.
For double immunoﬂuorescence, the sections were subjected to
2 sequential rounds of single-marker immunostaining, as
reported.15 The samples were incubated with mouse anti-human
CD68 (clone KP1, 1:100, Novus Biologicals) and then with Alexa
Fluor 488-conjugated secondary antibodies. Subsequently, mouse
anti-human HLA-DR/DP/DQ/DX that was labelled using the Zenon
Alexa Fluor-546 mouse IgG labelling kit (Molecular Probes) was
applied. The samples were imaged under a Leica TCS SP8 X
confocal laser scanning microscope (Leica Microsystems GmbH).
The ﬂuorochrome was excited by a pulsed supercontinuum white-
light laser (470–670 nm; 1-nm tuning step size). Speciﬁcally, CD68
was excited by a 499-nm-laser line and detected from 504 to 561
nm; HLA-DR/DP/DQ/DX was excited by a 557-nm laser line and
detected from 562 to 642 nm; and nuclei were visualised using
DAPI, which was excited with a 405-nm diode laser and detected
from 422 to 488 nm. The images were acquired in 512 × 512 scan
format using an HC PL APO 40 × /1.3 CS2 oil immersion objective
and a pinhole that was set to 1 airy unit. The data were analysed
using Leica LAS X rel. 3.1.1 (Leica Microsystems GmbH). Cells were
counted manually in 3 40X ﬁelds for each slide.
In vivo experiments
Six- to eight-week-old female FVB mice (Charles River) were
maintained in laminar ﬂow rooms at constant temperature and
humidity, with food and water given ad libitum. The experimental
protocols for the animal studies were approved by the Ethics
Committee for Animal Experimentation (OPBA) of Fondazione
IRCCS Istituto Nazionale dei Tumori di Milano according to
institutional guidelines.
We injected the FVB mice with syngeneic MI6 or
WTHER2_1 cells (1 × 106) into the mammary fat pad (m.f.p.),
as described.16 MI6 and WTHER2_1 cell lines were previously
established from spontaneous primary mammary carcinomas of
FVB-d16HER2 and FVB-huHER2 transgenic female mice, respec-
tively.16,17 Both the MI6 and WTHER2_1 m.f.p. models in FVB
mice strictly recapitulated morphologic, aggressive and
trastuzumab-responsive features of spontaneous primary mam-
mary tumours.16 When the tumours reached a mean volume of
about 100 mm3, the animals were randomised into 2 groups
(n= 4/group) to receive 2 intraperitoneal injections of 5 mg/kg
trastuzumab or saline on days 1 and 4 after randomisation.
Tumours were harvested and analysed 7 days after the
treatment outset.
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Flow cytometry
The cells that were derived from the digestion of the murine
mammary carcinomas with collagenase (300 U/ml) and hyalur-
onidase (100 U/ml) (StemCell Technologies) were analysed by
direct immunoﬂuorescence (IF) as described.18 Cells were stained
with the following antibodies: CD45APCeFluor780 (30-F11,
eBioscience), CD11bPE (MI/70, BD Bioscience), F4/80FITC (BM8,
eBioscience), and MHCIIAPC (M5/114.15.2, Miltenyi Biotec). Pur-
iﬁed rat monoclonal anti-mouse CD16/CD32 (eBioscience) was
used to prevent nonspeciﬁc binding to mouse Fc receptors. The
samples were analysed by gating on live cells after doublet
exclusion on a FACSCanto system (BD Bioscience) using FlowJo
(Tree Star Inc).
Statistical analysis
Differences between groups were determined by two-tailed
student’s t-test. Associations between categorical variables were
analysed by Fisher’s exact test, and correlations between
continuous variables were examined by Spearman correlation
analysis. A two-sided p-value of <0.05 was considered to be
signiﬁcant. The statistical analysis was performed using the
GraphPad Prism 5.01 package (GraphPad).
RESULTS
Molecular features associated with trastuzumab antitumour
activity
To identify the molecular features that are associated with
trastuzumab activity in the clinical setting, we analysed tumour
biopsies from patients with locally advanced primary HER2+ BC at
diagnosis who underwent brief exposure to trastuzumab
monotherapy.10 From a cohort of 28 patients, RNA samples with
sufﬁcient quality and quantity for gene expression proﬁling were
available for matched pretreatment and 21-day samples (Tru-cut
samples) for 17 subjects.
We compared the gene expression proﬁles of pretreatment
tumours with regard to the response to short-term trastuzumab.
Two types of responses were considered: clinical (C) and Ki67 (K).
C response was deﬁned as a reduction in tumour dimensions of at
least a 20% between post-therapy day 21 and the clinical
dimensions before the administration of trastuzumab. K response
was derived from positivity of pretreatment and post-treatment
biopsies for a cancer cell proliferation index (Ki67). Patients were
considered to be K responders if the number of Ki67-positive cells
in the post-treatment biopsy fell by at least 50% compared with
the pretreatment biopsy.
Figure 1a shows the distribution of responders. Not all cases
with a C response experienced a strong reduction in Ki67 levels,
whereas most tumours (86%) that were classiﬁed C non-
responders were also K non-responders. The tumour character-
istics by response are shown in Table S1. No differences in tumour
size, grade, hormone receptor status, proliferation index, or
intrinsic subtype were found between groups.
To examine the differences in gene expression proﬁles between
groups, we performed gene set enrichment analyses of pretreat-
ment biopsies by C and K responses. Compared with clinical
unresponsive cases (C−), clinical responsive cases (C+) showed
positive and negative enrichment, respectively, in pathways that
were related to immune cells and the tricarboxylic acid (TCA) cycle
(Fig. 1b and Table S2). PD1 signalling, which primarily comprises
MHC-II genes and T cell markers, was the most signiﬁcantly
enriched immune pathway in C responders compared with
K response Im
m
u
n
e
TC
A
EC
M
Pr
ol
ife
ra
tio
n
TK
 s
ig
na
lin
g
C
re
sp
on
se
K+
C+
C–
4
1
5
6
K–
NES
–2 –1.7
1.8 2.2
i: C+ vs. C–
ii: K+ vs. K–
13
12
11
M
H
C-
II 
m
et
ag
en
e
10
9
C+K+
p = 0.0696
p = 0.005
NES = 2.26
C+K– C–K–
iii: (C+K+) vs. (C+K–)
a b
c
d
Enrichment plot: REACTOME_PD1_SIGNALING
Enrichment profile Hits Ranking metric scores
0 2,500 5,000 7,500 10,000 12,500 15,000 17,500
Rank in ordered dataset
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
En
ric
hm
en
t s
co
re
 (E
S)
–1.5
–1.0
–0.5
0.0
0.5
1.0
Ra
n
ke
d 
lis
t m
et
ric
 (S
ign
al2
No
ise
)
Zero cross at 8014
'R' (positively correlated)
'NR' (negatively correlated)
Fig. 1 Molecular features of HER2+ BC biopsies associated with trastuzumab cytotoxic and cytostatic activity. a Scheme of the number of
tumours in each group. C+: responders (patients who experienced a reduction of at least 20% in tumour volume); C−: non-responders. K+:
responders (patients who experienced a reduction of at least 50% in the number of Ki67-positive cells in their tumours after treatment with
trastuzumab); K−: non-responders. b Averaged normalised enrichment score (NES) of pathways in each cluster signiﬁcantly enriched (FDR
<10%) in each comparison. Clusters were visualised using Cytoscape and labelled manually. Grey squares indicate no signiﬁcant enrichment. c
GSEA enrichment plots of PD1 gene set in C+ compared with C− tumours. NES, normalised enrichment score. d Expression of MHC-II
metagene according to tumour partition based on C and K responses. p-value by unpaired t-test
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non-responders (Fig. 1c). In contrast, K response was not
associated with immune pathways, but the tumours in K
responders (K+) versus non-responders (K−), were positively
enriched in pathways that were related to extracellular matrix
(ECM) organisation and receptor tyrosine kinase (RTK) signalling
and negatively enriched for TCA- and proliferation-related genes
(Fig. 1b and Table S2).
Among C responders, we also compared K responders versus K
non-responders (C+K+ vs C+K−) and noted enrichment in
immune pathways in C+K+ tumours, in addition to pathways
found between K+ versus K− patients, indicating that there is
greater enrichment in immune genes among clinical responders
in tumours that have a robust Ki67 response to trastuzumab
versus K-unresponsive cases (Figure S1). Accordingly, a greater
response to trastuzumab and chemotherapy at surgery was
observed in C+K+ cases than in the other groups (75% C+K+ vs
20% C+K− vs 43% C−K−), suggesting that robust and rapid
cytostatic and cytotoxic activity of trastuzumab is predictive of the
response to complete preoperative treatment.
Immune features that are associated with response to
trastuzumab
Based on the enrichment of immune genes in trastuzumab
responders, the function of the immune system in the cytotoxic
activity of trastuzumab, and the performance of immune
metagenes in predicting the response to trastuzumab in patients
who are treated in the neoadjuvant setting,5 we determined the
predictive ability of immune-related genes and their modulation
in identifying responders to trastuzumab. Based on the presence
of MHC-II, interferon-related genes, and T cell markers as leading
genes of the immune pathways that were enriched in responders
by GSEA (Table S2), we applied to the dataset the Rody immune
metagenes that are surrogate markers for the amounts of various
immune cell types in BC samples.13 Moreover, we used the
CIBERSORT tool to measure the relative fractions of immune cell
subsets in the samples.
Although we did not observe any differences in the CIBERSORT
22 immune subsets between responders and non-responders
(Figure S2), of the 6 Rody metagenes that we applied (MHC-I,
MHC-II, HCK, LCK, IFN, and STAT1), C+K+ tumours expressed
higher levels of the MHC-II metagene (p= 0.0696) than other
tumours (Fig. 1d). The lymphocyte-speciﬁc kinase (LCK) and
haematopoietic cell kinase (HCK) metagenes followed the same
trend, albeit insigniﬁcantly (Figure S3), as expected, based on the
high correlation between LCK and HCK with the MHC-II metagene
(r= 0.78, p= 0.0004 and r= 0.84, p < 0.0001, respectively), sup-
porting the function of immune genes and cells in the rapid
response to trastuzumab. Accordingly, unsupervised clustering of
samples at baseline with genes belonging to the Rody’s
metagenes showed a partition of C+K+ tumours and a high
expression of immune genes in these tumours (Figure S4).
In the analysis of the change in the expression of these
metagenes after 1 cycle of trastuzumab, there was a signiﬁcant
inverse correlation between the level of each MHC-II, LCK, and
HCK metagene in pretreatment biopsies and their induction by
trastuzumab (MHC-II: r=−0.63, p= 0.0067; LCK: r=−0.58, p=
0.0140; HCK: r=−0.60, p= 0.0104) (Fig. 2a and Figure S5). These
data indicate that immune cell inﬁltration is altered in tumours
that express low levels of these metagenes (i.e., non-C+K+
tumours) and that trastuzumab effects no such changes in
those with high basal expression. Notably, tumours in the
TRUP cohort that experienced the greatest increase in these
metagenes after trastuzumab treatment belonged to patients
who were responsive to complete preoperative trastuzumab-
based therapy (Fig. 2b-d). The fold-increase in MHC-II in
these tumours was signiﬁcantly higher than in non-responders
and in C+K+ tumours, in which trastuzumab did not signiﬁcantly
alter the immune proﬁle. In a cluster analysis of all tumours these
tru-cut biopsies were in the same cluster of C+K+ pretreatment
samples, indicating that in these tumours trastuzumab
increased immune inﬁltration up to the level of C+K+ tumours
(Figure S4).
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The inverse correlation between the up-modulation of immune
metagenes by trastuzumab and their basal expression was
validated in samples from the GSE76360 dataset (MHC-II: r=
−0.54, p < 0.0001; LCK: r=−0.55, p < 0.0001; HCK: r=−0.48, p=
0.0004, Figure S5), although the association with response was
unable to be determined due to the unavailability of data on the
response to short-term trastuzumab.
Modulation of MHC-II genes in responsive tumours
To determine whether the increase in MHC-II after trastuzumab
treatment reﬂects the recruitment and activation of immune cells
in the tumour microenvironment or its up-modulation in tumour
or stromal cells, we performed IHC of MHC-II using FFPE samples
of these biopsies. MHC-II positivity in tumour biopsies was almost
exclusive to inﬂammatory cells of the tumour microenvironment,
in which MHC-II-positive lymphocytes and macrophages were
detected (Fig. 3a).
The proportion of M1 macrophages, which express MHC-II
molecules,19 was the only subset that rose signiﬁcantly after
trastuzumab treatment in responsive tumours compared with
non-responders by CIBERSORT (Fig. 3b). Accordingly, a direct and
robust correlation was observed between the MHC-II metagene
and the induction of M1 by trastuzumab, supporting that greater
M1 macrophage inﬁltration on administration of trastuzumab
underlies the up-modulation of MHC-II in responsive tumours
(Fig. 3c). By immunoﬂuorescence, in certain samples of the TRUP
cohort, 70–90% of total CD68+ cells expressed MHC-II molecules
(data not shown).
To conﬁrm that the change in MHC-II expression reﬂects the
recruitment of immune cells in the tumour microenvironment by
trastuzumab, we used 2 murine mammary carcinoma models
available in our laboratory—MI6 and WTHER2—that overexpress
human HER2 and are responsive and resistant to trastuzumab,
respectively, when orthotopically implanted in syngeneic FVB
mice.20,16 Tumours that were derived from the injection of
MI6 in FVB mice, treated with 1 cycle of trastuzumab (1-week
treatment) and analysed when their dimensions were not yet
signiﬁcantly different from untreated tumours (Figure S6), con-
tained a higher proportion of MHC-II-positive cells than
untreated tumours (Fig. 4a). On the contrary, trastuzumab did
not induce this increase in resistant WTHER2 tumours (Fig. 4b and
Figure S6). MHC-II-positive cells in MI6 tumours were nearly
exclusively CD45+ cells (95 ± 1.7%), half of which were macro-
phages (CD11b+F4/80+: 52.5 ± 7.8%), independent of treatment,
and one-third of which were CD11b−F4/80− cells (33.3 ± 5.5%)
(Figure S7).
Circulating biomarkers reﬂect the immunomodulatory activity of
trastuzumab
Based on the ability of trastuzumab to recruit immune cells in the
tumour microenvironment, speciﬁcally in patients who respond to
trastuzumab-based therapy, we examined whether such immune
modulation also occurred in the blood, analysing immune cell
blood counts at baseline and at the time of Tru-cut biopsy. No
differences in circulating immune cells before treatment were
observed in patients by response (data not shown). Notably, the
total leucocyte count was altered by trastuzumab (based on the
post-treatment:pretreatment ratio) in responders compared with
non-responders. Among leucocytes, neutrophil levels changed
signiﬁcantly by response. Speciﬁcally, neutrophil counts rose in
non-responders, whereas clinical responders (C+K+) and patients
in whom trastuzumab had the highest immunomodulatory
activity experienced a decrease in circulating neutrophils at the
Tru-cut biopsy compared with baseline (Fig. 5a, b). ARG1, an
enzyme that is expressed primarily by neutrophils and M2
macrophages with immunosuppressive activity21 was signiﬁcantly
upregulated by trastuzumab in tumour tissue only in non-
responders (Figure S8), suggesting that circulating neutrophil
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counts reﬂect the immunosuppressive status of the tumour
microenvironment.
Accordingly, the proportion of neutrophils (CD11b+Ly6G+F4/
80− cells) fell in the spleen of mice that harboured responsive MI6
tumours and were treated with trastuzumab compared with
untreated animals (Fig. 5c and Figure S7), supporting the use of
this marker as an indicator of trastuzumab activity.
DISCUSSION
By analysing samples of a window of opportunity trial that offered
the possibility to dissect the activity of trastuzumab from that of
chemotherapy, we observed that the efﬁcacy of trastuzumab
treatment is associated primarily with features of the immune
system and that brief exposure to trastuzumab modiﬁes the
immune-related molecular properties of tumours, based on the
response to treatment.
Although 1 cycle of trastuzumab reduced Ki67 positivity in
nearly all tumours, Ki67 levels declined extensively primarily in
tumours with a low DNA replication rate, high tyrosine kinase
receptor activity, and high expression of extracellular matrix
genes. These data are consistent with the positive association
between low Ki67 positivity at baseline and the response to 3
cycles of trastuzumab alone, as reported by Mohsin et al.22.
In contrast, the size-reducing effect of trastuzumab was
strictly associated with enrichment in immune genes, indeed
tumours with high expression of immune genes at baseline were
responsive to 1 cycle of trastuzumab. This ﬁnding is consistent
with recent evidence that tumours with pre-existing high levels of
immune cells or genes in their tumour microenvironment respond
best to HER2-targeted therapies.5 The reduction in Ki67 levels by
trastuzumab was independent of immune features, but only cases
that achieved a C+K+ response beneﬁted from the entire
preoperative treatment, indicating that for trastuzumab to be
efﬁcacious, it must engage the immune system and block cell
proliferation.
In certain cases, trastuzumab upregulated MHC-II immune
genes, an increase that likely reﬂects the activation of the host
immune system cycle triggering an antitumour immune response
that could favour trastuzumab activity. These data are consistent
with another study in which short-term exposure to trastuzumab
upmodulated the CD4+ follicular helper T cell signature,23
considering that CD4+ T cells must recognise peptide-MHC-II
complexes to become activated. The relevance of the
trastuzumab-driven induction of immune inﬁltration in the
response to treatment is strongly supported by the clustering
analysis in which Tru-cut biopsies of responders are in the same
cluster of C+K+ pretreatment samples, highly expressing immune
genes.
Our gene expression and in situ analyses support the function
of macrophages in the cytotoxic activity of trastuzumab, based on
their ability to induce ADCP7 and engage the adaptive arm of the
immune system. They act as antigen-presenting cells to CD4+
T cells, which are crucial for trastuzumab activity.24 The similar
modulation of the LCK and HCK metagenes, reﬂecting the
inﬁltration of T cells and monocytes,13 indicates that trastuzumab
is active in tumours in which the entire immune system cycle is
stimulated or inducible by trastuzumab. These results were
conﬁrmed in murine models, wherein we observed an increase
in MHC-II positive cells after short-term trastuzumab treatment
only in a mouse model that was responsive to trastuzumab—not
in a trastuzumab-resistant model. Of note, increase of MHC-II
positive cells within MI6 tumour microenvironment was observed
before evidence of trastuzumab-induced tumour inhibition as
occurred in patients responsive to complete preoperative
trastuzumab-based therapy. Further studies are required to
understand which signals are responsible for the trastuzumab-
induced recruitment of MHC-II positive immune cells in the
tumour microenvironment of responsive patients. One possible
explanation derives from the well-known interaction between
macrophages and apoptotic cells.25 In this context, as suggested
by the enrichment of apoptosis pathway (Reactome) we observed
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in Tru-cut samples of responders vs non-responders (NES= 1.63,
p < 0.0001), recruitment of MHC-II positive cells could derive from
the induction of apoptotic cell death by trastuzumab that was
described to be one mechanism of antibody activity.22
The lower levels of circulating neutrophils in patients who
beneﬁt from trastuzumab indicate the recruitment of these cells
into the tumour microenvironment, where they likely participate
in trastuzumab activity through their ability to mediate ADCC, as
demonstrated in HER2-positive xenograft models.26 However,
levels of circulating neutrophils may also inform about the
activation status of patient immune system. Indeed, it is becoming
evident that neutrophils can support tumour growth, based on
the elevated counts of myeloid-derived suppressor cells (MDSCs)
in the blood of patients with advanced cancer, reﬂecting tumour
immune evasion.27 Whereas the reduction in circulating neutro-
phils in C+K+ tumours after trastuzumab treatment might be
attributed to a decreased tumour burden due to the cytotoxic
activity of trastuzumab,28 the differences between clinical
responders and non-responders are unlikely to stem from
disparities in tumour burden, because no differences in tumour
dimension were appreciable at the time of the Tru-cut biopsy.
This pattern also holds for MI6 mice that were treated with or
without trastuzumab. It is possible that these differences are
attributed to the varying expansion of these cells, as induced by
trastuzumab itself or through changes in the tumour cells. The
signiﬁcant negative correlation between circulating neutrophils at
the diagnosis and the response to short-term trastuzumab favours
the immune-suppressive activity of neutrophils in cancer patients,
supporting the greater cytotoxic activity of trastuzumab in
patients with low immune suppression.
Moreover, the lower basal expression of arginase in fast-
responding tumours (C+K+) compared with other tumours,
supports the rapid cytotoxic activity of trastuzumab in these
tumours due to a favourable microenvironment, which is enriched
in effector immune cells and has low immune suppression.
Notably, patients who did not respond to treatment had higher
circulating neutrophil and ARG1 levels in the tumour microenvir-
onment at the time of Tru-cut biopsy, supporting greater immune
suppression by trastuzumab, which is one explanation for its
missed activity. Future research should determine the mechanism
by which trastuzumab increases neutrophil levels in nonrespon-
sive tumours to improve the activity of trastuzumab through
immunotherapeutic strategies (e.g., anti-MDSC therapy) for
patients who do not respond to treatment. Because the number
of MDSCs modulates the activity of immune checkpoint inhibi-
tors,29 evaluating the function of neutrophils in the response to
trastuzumab could guide the development of new combinations
of trastuzumab and anti-PD-L1 drugs, a promising approach for
HER2+ tumours that has been demonstrated in preclinical
models30 and in a trial of HER2+ BC patients.31
The limitations of this study include its small sample size and
the lack of adequate tumour samples for all patients before
treatment and after short-term exposure necessary to characterise
immune inﬁltrates according to trastuzumab-response and to
trastuzumab-induced apoptosis. Nevertheless, our data conﬁrm
the ﬁndings from preclinical studies on the mechanism of action
of trastuzumab5 in human samples.
Our analyses demonstrate that short-term trastuzumab induces
immune-related biomarkers that reﬂect the beneﬁt from trastu-
zumab and activates the adaptive immune system, which has
been crucial for the eradication of BC on treatment with
trastuzumab in preclinical24,30,32 and clinical studies.33 The
modulation of MHC-II by trastuzumab, primarily in patients with
low basal immune inﬁltration, is consistent with our data on the
change in NKG2D, a marker of NK and trastuzumab activity,34
suggesting that immune modulation by trastuzumab occurs only
in patients in whom immune evasion has not been engaged.
This study, despite its exploratory nature, has strong transla-
tional relevance. Clinically it should prompt the examination of
tissue-associated and circulating midcourse biomarkers of the
efﬁcacy of trastuzumab and compare them with basal pretreat-
ment biomarkers in larger studies in which a window of exposure
to anti-HER2 therapies without chemotherapy is incorporated into
the trial design. The use of these biomarkers could become a
valuable clinical approach for guiding patients toward the ideal
regimen after brief exposure to trastuzumab. Moreover, in an era
in which dual HER2 blockade has proven to be highly
effective,35,36 this program would help identify patients who
already beneﬁt from single-agent trastuzumab with or without
chemotherapy, supporting a de-escalation strategy.
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